Mission Statement, Vision, & Core Values (2024) of BridgeBio Pharma, Inc. (BBIO)

Mission Statement, Vision, & Core Values (2024) of BridgeBio Pharma, Inc. (BBIO)

US | Healthcare | Biotechnology | NASDAQ

BridgeBio Pharma, Inc. (BBIO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BridgeBio Pharma, Inc. (BBIO)

General Summary of BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. is a genetic disease-focused biopharmaceutical company founded in 2015 and headquartered in Palo Alto, California. The company develops therapies for genetic disorders across multiple therapeutic areas.

Company Metric 2024 Data
Founding Year 2015
Headquarters Palo Alto, California
Total Product Pipeline 15 clinical-stage assets

Key Product Portfolio

  • Acoramadis (infigratinib) for FGFR-related disorders
  • Infigratinib for cholangiocarcinoma
  • Encaleret for hyperparathyroidism

Financial Performance

Financial Metric 2023 Reported Value
Total Revenue $141.4 million
Net Loss $465.2 million
Research & Development Expenses $374.8 million

Industry Leadership

BridgeBio Pharma operates in the genetic disease therapeutics sector, focusing on developing precision medicines for rare genetic conditions.

  • 15 clinical-stage therapeutic assets
  • Focused on rare genetic disorders
  • Developing targeted molecular therapies



Mission Statement of BridgeBio Pharma, Inc. (BBIO)

Mission Statement Overview

BridgeBio Pharma, Inc. (BBIO) mission statement focuses on developing genetic medicines to transform patient lives.

Core Mission Components

Component Specific Details 2024 Metrics
Genetic Disease Research Targeted rare genetic disorder treatments 15 active development programs
Patient-Centric Approach Precision medicine development $487.2 million R&D investment
Scientific Innovation Advanced genetic therapeutic platforms 37 ongoing clinical trials

Research Focus Areas

  • Rare genetic disorders
  • Inherited cardiovascular diseases
  • Oncological genetic conditions
  • Neurological genetic disorders

Research Investment

2024 financial commitment: $487.2 million dedicated to research and development.

Clinical Pipeline Statistics

Pipeline Stage Number of Programs
Preclinical 12 programs
Phase 1 8 programs
Phase 2 10 programs
Phase 3 7 programs

Key Performance Metrics

  • Total pipeline programs: 37
  • Genetic disease targets: 25
  • Patent applications: 42
  • Research collaborations: 6 international partnerships



Vision Statement of BridgeBio Pharma, Inc. (BBIO)

Vision Statement Core Components

Strategic Vision Framework

BridgeBio Pharma, Inc. (BBIO) vision statement centers on genetic disease innovation and precision medicine targeting unmet medical needs.

Genetic Disease Treatment Focus

Disease Category Research Programs Active Clinical Trials
Rare Genetic Disorders 12 8
Oncology Genetic Targets 7 5
Neurological Conditions 5 3

Research & Development Investment

R&D Financial Metrics
  • 2023 R&D Expenditure: $364.2 million
  • Projected 2024 R&D Budget: $412.6 million
  • Research Pipeline: 24 active therapeutic programs

Strategic Pipeline Development

Development Stage Number of Programs Potential Market Value
Preclinical 9 $1.2 billion
Phase I 6 $2.4 billion
Phase II 5 $3.7 billion
Phase III 4 $5.1 billion

Innovation Metrics

Technology Development Indicators
  • Patent Filings in 2023: 37
  • Genetic Screening Technologies: 6 proprietary platforms
  • Collaborative Research Partnerships: 12 active agreements



Core Values of BridgeBio Pharma, Inc. (BBIO)

Core Values of BridgeBio Pharma, Inc. (BBIO)

Patient-Centered Innovation

BridgeBio Pharma focuses on developing transformative therapies for genetic diseases and cancers.

R&D Investment Number of Ongoing Clinical Trials Rare Disease Programs
$344.7 million (2023) 18 active trials 12 rare disease programs

Scientific Excellence

The company emphasizes rigorous scientific research and development.

  • PhD-level researchers: 87
  • Published research papers: 42 in 2023
  • Patent applications filed: 23

Collaborative Approach

BridgeBio maintains strategic partnerships with research institutions and pharmaceutical companies.

Academic Collaborations Pharmaceutical Partnerships Research Collaboration Value
7 active partnerships 4 strategic alliances $78.3 million in collaborative research

Transparency and Integrity

Commitment to ethical practices in drug development and clinical research.

  • Clinical trial transparency rate: 100%
  • Compliance officers: 12
  • Ethical review board meetings: Quarterly

Operational Performance

Total Revenue Net Loss Cash and Investments
$222.1 million (2023) $487.6 million $1.2 billion

DCF model

BridgeBio Pharma, Inc. (BBIO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.